Literature DB >> 30650350

Mapping the Human Kinome in Response to DNA Damage.

Michel Owusu1, Peter Bannauer1, Joana Ferreira da Silva1, Thanos P Mourikis2, Alistair Jones2, Peter Májek1, Michael Caldera1, Marc Wiedner1, Charles-Hugues Lardeau3, André C Mueller1, Jörg Menche1, Stefan Kubicek4, Francesca D Ciccarelli2, Joanna I Loizou5.   

Abstract

We provide a catalog for the effects of the human kinome on cell survival in response to DNA-damaging agents, covering all major DNA repair pathways. By treating 313 kinase-deficient cell lines with ten diverse DNA-damaging agents, including seven commonly used chemotherapeutics, we identified examples of vulnerability and resistance that are kinase specific. To investigate synthetic lethal interactions, we tested the response to carmustine for 25 cell lines by establishing a phenotypic fluorescence-activated cell sorting (FACS) assay designed to validate gene-drug interactions. We show apoptosis, cell cycle changes, and DNA damage and proliferation after alkylation- or crosslink-induced damage. In addition, we reconstitute the cellular sensitivity of DYRK4, EPHB6, MARK3, and PNCK as a proof of principle for our study. Furthermore, using global phosphoproteomics on cells lacking MARK3, we provide evidence for its role in the DNA damage response. Our data suggest that cancers with inactivating mutations in kinases, including MARK3, are particularly vulnerable to alkylating chemotherapeutic agents.
Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DNA damage; carmustine; chemotherapeutics; kinase; kinome; synthetic lethality; temozolomide

Mesh:

Year:  2019        PMID: 30650350     DOI: 10.1016/j.celrep.2018.12.087

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  6 in total

1.  Peptide fusion improves prime editing efficiency.

Authors:  Minja Velimirovic; Larissa C Zanetti; Max W Shen; James D Fife; Lin Lin; Minsun Cha; Ersin Akinci; Danielle Barnum; Tian Yu; Richard I Sherwood
Journal:  Nat Commun       Date:  2022-06-18       Impact factor: 17.694

2.  The Clinical Kinase Index: A Method to Prioritize Understudied Kinases as Drug Targets for the Treatment of Cancer.

Authors:  Derek Essegian; Rimpi Khurana; Vasileios Stathias; Stephan C Schürer
Journal:  Cell Rep Med       Date:  2020-10-20

Review 3.  Synthetic Lethal Interactions for Kinase Deficiencies to DNA Damage Chemotherapeutics.

Authors:  Lydia Robinson-Garcia; Joana Ferreira da Silva; Joanna I Loizou
Journal:  Cancer Res       Date:  2019-08-06       Impact factor: 12.701

4.  DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer.

Authors:  Rui-Xue Huang; Ping-Kun Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-05-01

Review 5.  Emerging roles of DYRK2 in cancer.

Authors:  Vasudha Tandon; Laureano de la Vega; Sourav Banerjee
Journal:  J Biol Chem       Date:  2021-01-07       Impact factor: 5.157

6.  The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma.

Authors:  Hidenori Machino; Syuzo Kaneko; Masaaki Komatsu; Noriko Ikawa; Ken Asada; Ryuichiro Nakato; Kanto Shozu; Ai Dozen; Kenbun Sone; Hiroshi Yoshida; Tomoyasu Kato; Katsutoshi Oda; Yutaka Osuga; Tomoyuki Fujii; Gottfried von Keudell; Vassiliki Saloura; Ryuji Hamamoto
Journal:  Commun Biol       Date:  2022-01-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.